Tiger BioSciences LLC

CONSHOHOCKEN, Pa. and CLEVELAND, Feb. 13, 2025 /PRNewswire/ -- Novo Health Care Service and Encore Surgical Supplies developed the HealPACK as an innovative surgical dressing solution that enhances the post-surgery healing process, delivered to the patient's door for treatment in the comfort of the patient's home. HealPACK is a convenience pack of premium line of surgical dressing products trusted by physicians nationwide. HealPACK comes with a specifically development HealPACK app that supports the prescription and insurance verification process needed to order the product. The app also assists with relevant documentation required for proper reimbursement of the dressings. Each physician-prescribed, patient-specific order is shipped directly to the patient, eliminating risks around the interruption of continued care, increasing patient's wound care compliance, and saving physicians' practice time and money. Miro Kesic, Encore's CEO said, "In a short amount of time, we have become a market leader in empowering physicians to deliver post operative and conservative therapies for their patients. With a great team, advanced technology, and timely execution, Encore has delivered a superior platform to the market. This has resulted in the exponential growth and success of Encore Surgical." Neall French, Encore's President added, "The next phase in continuing to deliver constant innovation and enhancements, is to align the HealPACK with one the industry's best, in Tiger BioSciences. Tiger has an exceptional leadership team, impressive portfolio of companies, and a relentless mission in delivering superior clinical outcomes for patients." "The HealPACK and HealAPP is a fantastic addition to Tiger's already impressive Wound Care product offering. Encore Surgical Dressing, LLC will be a new division of Tiger BioSciences that will have access to our vast network of customers in the orthopedic, podiatry as well as plastic surgery divisions. We are looking forward to the continuation of collaboration with Miro's and Nealls's team to ensure that more patients can benefit from our overall product offering," said Oliver Burckhardt, Co-CEO of Tiger BioSciences. About Tiger BioSciences: At Tiger BioSciences, we lead the way in global regenerative medicine. We believe that cell and tissue technologies can drive the future of regenerative medicine. Innovations around compliant tissue engineering, tissue processing and medical devices that support tissue-based technologies is at the heart of what we do. Through vertical integration, tiger and its wholly owned subsidiaries offer all relevant aspects of modern engineering and related, complementary technologies. From idea conception, pre-clinical and clinical research, reimbursement, to processing and compliant distribution. For additional information, please contact: Larry R. ("Buzz") Wood, Jr. Chief Legal Officer [email protected] or Craig Waters, Chief Financial Officer, Novo Healthcare Services [email protected] SOURCE Encore Clinical Services WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Tiger Aesthetics Medical, LLC today announced its acquisition of substantially all of the assets associated with the Sientra Inc. breast implant business. This strategic acquisition will complement Tiger Aesthetics’ upcoming adipose cell and tissue product launches designed to provide new treatment options for plastic surgeons and patients. Moving forward, Sientra will become a division of Tiger Aesthetics Medical LLC. About Tiger Aesthetics Medical, LLC Tiger Aesthetics, a wholly owned subsidiary of Tiger Biosciences, has developed innovative regenerative medicine products designed for aesthetic applications. The timing of this acquisition aligns with the vision to bring to market allogeneic adipose tissues to plastic and reconstructive surgeons and their patients. By integrating the Sientra brand, Tiger Aesthetics can now provide a comprehensive portfolio of products. With a focus on regenerative medicine, Tiger is committed to leveraging Sientra’s market presence and existing product offering to deliver new, cutting-edge products that meet the evolving needs of aesthetic practitioners and their patients. "We are excited to bring the Sientra brand into our portfolio," said Oliver Burckhardt, Co-CEO of Tiger Aesthetics Medical, LLC. "This acquisition underscores our dedication to be a powerful player in the aesthetics market. By combining Sientra's surgical assets with our expertise and resources in tissue engineering, we are well positioned to give an even greater value to our customers and to drive market share with never-seen innovations into augmentation and reconstructive surgery." Tiger Aesthetics remains committed to upholding the product standards of quality, product returns and warranty policy customary in the industry. The integration of the newly acquired assets into its operations, with a focus on ensuring a seamless transition for customers and stakeholders has begun and is well on its way. Tiger Aesthetics has committed to maintaining manufacturing and operations at Sientra’s Franklin, WI manufacturing facilities. Their dedication to excellence and patient safety is crucial to the brand’s long-term success. "We see tremendous potential in the synergies between our organizations," added Scott Madden, Co-CEO of Tiger Aesthetics Medical, LLC. "Together, we will continue to drive innovation, advance patient care, and change the look and feel of the aesthetics industry." About Tiger Aesthetics Medical, LLC: Tiger Aesthetics Medical is a wholly owned subsidiary of Tiger Biosciences, a leading tissue engineering company based out of Conshohocken, PA. Our product portfolio focuses on the augmentation and reconstruction of soft tissue. Regenerative medicine solutions are a critical part of our visionary product offering and product development strategy. Tiger’s product portfolio consists of silicone breast implants, tissue expanders as well as state of the art autologous and allogeneic adipose products and fat transfer technologies.

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Spirair™, an early-stage company pioneering minimally invasive solutions that help ENTs advance care for their patients, today announced the appointment of Benjamin Bishop as its chief executive officer. The company is developing a novel therapy for symptomatic nasal septal deviation (NSD) that supports and straightens minor deviations in the septum with a bioabsorbable implant. Septal deviation is one of the most common causes of nasal airway obstruction (NAO), a condition that makes it difficult to breathe through the nose. 1 Despite advancements in techniques, treatments and technologies in the otolaryngology (ENT) field broadly, NSD correction has remained stagnant for years. Treatment options for symptomatic NSD have been limited to either over-the-counter medications to alleviate symptoms or invasive surgical techniques to address the structural issues that cause these symptoms. Traditional septoplasty or septorhinoplasty are the most common surgical treatment options for NSD. Septoplasty can require significant time away from work, with approximately 40% of patients requiring two or more weeks off for recovery. 2 “ Our team is partnering with leading ENT advisors and industry veterans to develop minimally invasive solutions that provide strong outcomes and a better experience for their patients,” said Bishop. “ I’m proud to join this team of innovators who are working to add treatment options to physicians’ toolkits to help them continue supporting their patients.” Bishop joins Spirair with two decades of commercial leadership experience across the medical, surgical and aesthetic industries. He has a proven track record for successfully launching disruptive technologies and establishing new markets, playing a key role in developing high-growth companies like Revelle Aesthetics, Revance Therapeutics, and Access Closure. Bishop also led sales and marketing at Arrinex – the company that developed ClariFix ® , an ENT technology for chronic rhinitis – prior to its acquisition by Stryker in 2019. Spirair got its start in the Stanford Biodesign Innovation Fellowship, a program that equips aspiring innovators with a proven, repeatable process to identify important health-related needs, invent novel health technologies to address them, and prepare to implement those products into patient care. Founders James Kintzing, Ph.D. and Brandon McCutcheon, M.D. were co-fellows in the program and identified an opportunity in the ENT space when they discovered the unmet need for a minimally invasive nasal septal deviation correction therapy to help address nasal airway obstruction. “ As an alumna of the Stanford Biodesign Innovation Fellowship myself, I’ve seen firsthand how this program successfully supports groundbreaking ideas in healthcare technology – and Spirair is a shining example of this innovation,” said Kate Garrett, managing partner at Sonder Capital, assistant director of the Stanford Biodesign Innovation Fellowship and chair of Spirair’s board of directors. “ Benjamin Bishop has an outstanding track record as a commercial leader and I’m thrilled to welcome him to Spirair as its chief executive officer as we begin this exciting next stage of growth.” Spirair’s nasal septal deviation therapy is currently being investigated as part of two IRB-approved nonsignificant risk (NSR) U.S. clinical trials. The company expects to begin a Series B fundraising round and initiate its commercialization efforts in 2024. 1 Clark DW, Del Signore AG, Raithatha R, Senior BA. Nasal airway obstruction: Prevalence and anatomic contributors. Ear Nose Throat J. 2018 Jun;97(6):173-176. doi: 10.1177/014556131809700615. PMID: 30036414. 2 Chidambaram A, et al. Anticipated absence from work ('sick leave') following routine ENT surgery: are we giving the correct advice? A postal questionnaire survey. Clin Otolaryngol Allied Sci. 2001 Apr;26(2):104-8. doi: 10.1046/j.1365-2273.2001.00433.x. PMID: 11309049. About Spirair Spirair is an early-stage company pioneering minimally invasive solutions that help ENTs advance care for their patients by providing strong outcomes and a better patient experience. Spirair is committed to developing new therapies that can easily integrate in any ENT’s treatment algorithms so they can help more of their patients breathe better. Its first product is a novel minimally invasive option for symptomatic NSD that supports and straightens minor deviations in the septal cartilage and can be conveniently and safely performed under local anesthesia in any site of service as part of standard septoplasty techniques. The company got its start through the Stanford Biodesign Innovation Fellowship, a program that equips aspiring innovators with a proven, repeatable process to identify important health-related needs, invent novel health technologies to address them, and prepare to implement those products into patient care.